Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases
Summary
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched today with $100 million in financing. The financing will be used to support further advancement of the companys proprietary platform and its discovery pipeline of novel covalent molecules, initially focused on immunology.We created Matchpoint to harness the powerful properties of covalency and enable the targeting of disease-causing proteins otherwise unamenable to small molecule intervention, said Andre Turenne, President and Chief Executive Officer of Matchpoint. It also enables a thorough assessment of a molecules selectivity profile early in the discovery process, said Nathanael Gray, PhD, Matchpoint co-founder and Professor of Chemical and Systems Biology at Stanford University. Our platform, combining proprietary chemoproteomics approaches and artificial intelligence, is overcoming this limitation and the word-class team assembled at Matchpoint is uniquely positioned to translate these advances into the next generation of precision covalent medicines, said Edward Chouchani, PhD, Matchpoint co-founder and Associate Professor of Cell Biology at Harvard Medical School and Dana-Farber Cancer Institute.In addition to Drs. Gray and Chouchani, Matchpoints founders include Dr. Jianwei Che from Dana-Farber Cancer Institute and Dr. Tinghu Zhang from Stanford University.